Amphastar Pharmaceuticals, Inc.AMPHEarnings & Financial Report
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMPH Q4 FY2025 Key Financial Metrics
Revenue
$183.1M
Gross Profit
$85.7M
Operating Profit
$35.6M
Net Profit
$24.4M
Gross Margin
46.8%
Operating Margin
19.4%
Net Margin
13.3%
YoY Growth
-1.8%
EPS
$0.51
Amphastar Pharmaceuticals, Inc. Q4 FY2025 Financial Summary
Amphastar Pharmaceuticals, Inc. reported revenue of $183.1M (down 1.8% YoY) for Q4 FY2025, with a net profit of $24.4M (down 35.7% YoY) (13.3% margin). Cost of goods sold was $97.4M, operating expenses totaled $50.1M.
Key Financial Metrics
| Total Revenue | $183.1M |
|---|---|
| Net Profit | $24.4M |
| Gross Margin | 46.8% |
| Operating Margin | 19.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Amphastar Pharmaceuticals, Inc. Q4 FY2025 revenue of $183.1M breaks down across 6 segments, led by Other Products at $62.4M (34.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other Products | $62.4M | 34.1% |
| Baqsimi | $46.7M | 25.5% |
| Primatenemist | $27.9M | 15.3% |
| Epinephrine | $17.1M | 9.3% |
| Lidocaine | $14.9M | 8.1% |
| Glucagon | $14.1M | 7.7% |
Amphastar Pharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Amphastar Pharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other Products and Baqsimi) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other Products | $62.4M | $64.1M | $53.1M | $50.0M |
| Baqsimi | $46.7M | $53.6M | $46.7M | $38.4M |
| Primatenemist | $27.9M | $28.8M | $22.9M | $29.1M |
| Epinephrine | $17.1M | $18.8M | $16.2M | $18.6M |
| Lidocaine | $14.9M | $12.9M | $15.0M | $13.6M |
Amphastar Pharmaceuticals, Inc. Annual Revenue by Year
Amphastar Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $719.9M).
Amphastar Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Amphastar Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $183.1M | -1.8% | $24.4M | 13.3% |
| Q3 FY2025 | $191.8M | +0.3% | $17.4M | 9.0% |
| Q2 FY2025 | $174.4M | -4.4% | $31.0M | 17.8% |
| Q1 FY2025 | $170.5M | -0.8% | $25.3M | 14.8% |
| Q4 FY2024 | $186.5M | +4.7% | $38.0M | 20.4% |
| Q3 FY2024 | $191.2M | +5.9% | $40.4M | 21.1% |
| Q2 FY2024 | $182.4M | +25.2% | $37.9M | 20.8% |
| Q1 FY2024 | $171.8M | +22.7% | $43.2M | 25.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $171.8M | $182.4M | $191.2M | $186.5M | $170.5M | $174.4M | $191.8M | $183.1M |
| YoY Growth | 22.7% | 25.2% | 5.9% | 4.7% | -0.8% | -4.4% | 0.3% | -1.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.57B | $1.49B | $1.55B | $1.58B | $1.63B | $1.62B | $1.67B | $1.63B |
| Liabilities | $902.0M | $778.2M | $817.5M | $845.2M | $875.0M | $857.9M | $889.5M | $840.5M |
| Equity | $672.4M | $713.3M | $727.7M | $732.3M | $751.3M | $757.5M | $776.7M | $788.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $55.3M | $69.1M | $60.0M | $29.0M | $35.1M | $35.6M | $52.6M | $32.9M |